GuestSeminars
Zoom Session
Add to Calendar 2022-03-18 12:00:00 2022-03-18 13:00:00 GuestSeminars@UCIBIO | Hélder A. Santos Modulating biomaterial-cell interactions for personalized targeting and regenerative therapies Hélder A. Santos, Division of Pharmaceutical Chemistry and Technology, Helsinki One Health (HOH)   Host: Sérgio Sousa, UCIBIO Porto   ZOOM link: https://bit.ly/GuestSeminarsUCIBIO ID da reunião: 865 7786 0516 Senha: 805165   Abstract: The recent cutting-edge advances on nanomaterials is anticipated to overcome some of the therapeutic window and clinical applicability of many drug/peptide molecules and can also act as innovative theranostic platforms and tool for the clinic in the future [1-4]. In the last decade, research on cancer iand cardiovascular diseases resulted in a new set of potential treatments with promising results in the clinics [5-9]. Amongst the different experimental treatments, active cancer immunotherapy and targeted to the injured heart hold great promise for the future treatment of these diseases. In this work, prominent nanosystems, such as biohybrid nanocomposites made of different nanoparticles (porous silicon and oncolytic virus) and cancer cell-based membrane materials are presented and discussed as potential platforms for the individualization of medical intervention and biomedical applications. Examples on how these biohybrid nanomaterials can be prepared and scaled-up, as well as how they can be used to enhance the drug’s targetability, intracellular drug delivery for both cancer chemo- and immune-therapy applications as well as other applications, will be highlighted and discussed. Overall, our results suggest that biohybrid nanomaterials are a versatile and advanced platform for treatment of different diseases with an interesting potential for present and future clinical impact given its easy tailorability to each patient. [1] H. Zhang, W. Cui, X. Qu, H. Wu, L. Qu, X. Zhang, E. Mäkilä, J. Salonen, Y.-Q. Zhu, Z. Yang, D. Chen, H. A. Santos*, M. Hai*, D. A. Weitz*, Proc. Natl. Acad. Sci. U.S.A. 2019, 116, 7744. [2] Z. Liu*, Y. Li, W. Li, C. Xiao, D. Liu, C. Dong, M. Zhang, E. Mäkilä, M. Kemell, J. Salonen, J. T. Hirvonen, H. Zhang, D. Zhou, X. Deng, H. A. Santos*, Adv. Mater. 2018, 30, 1703393. [3] M. P.A. Ferreira*, V. Talman, G. Torrieri, D. Liu, G. Marques, K. Moslova, Z. Liu, J. F. Pinto, J. Hirvonen, H. Ruskoaho, H. A. Santos*, Adv. Funct. Mater. 2018, 28, 1705134. [4] M. P.A. Ferreira*, S. Ranjan, S. Kinnunen, A. Correia, V. Talman, E. Mäkilä, B. Barrios-Lopez, M. Kemell, V. Balasubramanian, J. Salonen, J. Hirvonen, H. Ruskoaho, A. J. Airaksinen, H. A. Santos*, Small 2017, 13, 1701276.  [5] F. Fontana*, M.-A. Shahbazi, D. Liu, H. Zhang, E. Mäkilä, J. Salonen, J. T. Hirvonen, H. A. Santos*, Adv. Mater. 2017, 29, 1603239. [6] F. Fontana, M. Fusciello, C. Groeneveldt, C. Capasso, J. Chiaro, S. Feola, Z. Liu, E. M. Mäkilä, J. J. Salonen, J. T. Hirvonen, V. Cerullo*, H. A. Santos*, ACS Nano 2019, 13, 6477. [7] T. Yong, X. Zhang, N. Bie, H. Zhang, X. Zhang, F. Li, A. Hakeem, J. Hu, L. Gan, H. A. Santos*, X. Yang*, Nature Commun. 2019, 10, 3838. [8] M. Fusciello, F. Fontana, S. Tähtinen, C. Capasso, S. Feola, B. Martins, J. Chiaro, K. Peltonen, L. Ylösmäki, E. Ylösmäki, F. Hamdan, O. K. Kari, J. Ndika, H. Alenius, A. Urtti, J. T. Hirvonen, H. A. Santos*, V. Cerullo*, Nature Commun. 2019, 10, 5747. [9] J. Zhang, Cheng Ji, Hongbo Zhang, Hui Shi, Fei Mao, Hui Qian, Wenrong Xu, Dongqing Wang, Jianming Pan, Xinjian Fang*, Hélder A. Santos*, Xu Zhang*, Sci. Adv. 2022, 8, eabj8207.     Short CV: Prof. Santos (D.Sc. Tech., Chem. Eng.) is a Full Professor in the Department of Biomedical Engineering and Head of the Department of Biomedical Engineering at the University of Groningen/University Medical Center Groningen. He was previously Full Professor in Pharmaceutical Nanotechnology, Director of Doctoral Program in Drug Research (University of Helsinki), Fellow Member of Helsinki Institute of Life Science, Director of the FinPharmaNet in Finland, and Chair of CRS Focus Group in Nanomedicine and Nanoscale Delivery. He is also Research Director and Head of Nanomedicines and Biomedical Engineering Group at the University of Helsinki, Faculty of Pharmacy. Prof. Santos is also the Chairman and co-founder of Capsamedix Oy, and Coordinator of H2020 EU MSCA-ITN P4 FIT network. He holds Visiting Professorships at the Shanghai Jiao Tong University School of Medicine (China) and University of Tartu (Estonia).  Prof. Santos research interests include the development of nanoparticles/nanomedicines and biomaterials for biomedical applications, particularly cancer and heart diseases. His lab makes the unique bridge between medical engineering, pharmaceutical nanotechnology and tissue engineering by combining unique techniques to develop novel therapeutic formulations, including industrial scale-up validation, batch-to-batch reproducibility, and controllability of the biomaterials’ physicochemical properties for translation into the clinic.  He is co-author of +400 publications (+14500 citations; h-index = 70) and 4 patents. He has +181 invited talks around the world. Prof. Santos has received prestigious awards/grants, e.g., the "Talent Prize in Science" in 2010 attributed by the Portuguese Government, ERC Starting Grant in 2013 and ERC Proof-of-Concept Grant in 2018, Young Researcher Award in 2013 attributed by Faculty of Pharmacy, the Academy of Finland Award for Social Impact in 2016, and the CRS Young Investigator Award 2021. Zoom Session UCIBIO info@simbiose.com Europe/Lisbon public
helder santos

Modulating biomaterial-cell interactions for personalized targeting and regenerative therapies

Hélder A. Santos, Division of Pharmaceutical Chemistry and Technology, Helsinki One Health (HOH)

 

Host: Sérgio Sousa, UCIBIO Porto

 

ZOOM link: https://bit.ly/GuestSeminarsUCIBIO

ID da reunião: 865 7786 0516

Senha: 805165
 

Abstract: The recent cutting-edge advances on nanomaterials is anticipated to overcome some of the therapeutic window and clinical applicability of many drug/peptide molecules and can also act as innovative theranostic platforms and tool for the clinic in the future [1-4]. In the last decade, research on cancer iand cardiovascular diseases resulted in a new set of potential treatments with promising results in the clinics [5-9]. Amongst the different experimental treatments, active cancer immunotherapy and targeted to the injured heart hold great promise for the future treatment of these diseases. In this work, prominent nanosystems, such as biohybrid nanocomposites made of different nanoparticles (porous silicon and oncolytic virus) and cancer cell-based membrane materials are presented and discussed as potential platforms for the individualization of medical intervention and biomedical applications. Examples on how these biohybrid nanomaterials can be prepared and scaled-up, as well as how they can be used to enhance the drug’s targetability, intracellular drug delivery for both cancer chemo- and immune-therapy applications as well as other applications, will be highlighted and discussed. Overall, our results suggest that biohybrid nanomaterials are a versatile and advanced platform for treatment of different diseases with an interesting potential for present and future clinical impact given its easy tailorability to each patient.

[1] H. Zhang, W. Cui, X. Qu, H. Wu, L. Qu, X. Zhang, E. Mäkilä, J. Salonen, Y.-Q. Zhu, Z. Yang, D. Chen, H. A. Santos*, M. Hai*, D. A. Weitz*, Proc. Natl. Acad. Sci. U.S.A. 2019, 116, 7744.
[2] Z. Liu*, Y. Li, W. Li, C. Xiao, D. Liu, C. Dong, M. Zhang, E. Mäkilä, M. Kemell, J. Salonen, J. T. Hirvonen, H. Zhang, D. Zhou, X. Deng, H. A. Santos*, Adv. Mater. 2018, 30, 1703393.
[3] M. P.A. Ferreira*, V. Talman, G. Torrieri, D. Liu, G. Marques, K. Moslova, Z. Liu, J. F. Pinto, J. Hirvonen, H. Ruskoaho, H. A. Santos*, Adv. Funct. Mater. 2018, 28, 1705134.
[4] M. P.A. Ferreira*, S. Ranjan, S. Kinnunen, A. Correia, V. Talman, E. Mäkilä, B. Barrios-Lopez, M. Kemell, V. Balasubramanian, J. Salonen, J. Hirvonen, H. Ruskoaho, A. J. Airaksinen, H. A. Santos*, Small 2017, 13, 1701276. 
[5] F. Fontana*, M.-A. Shahbazi, D. Liu, H. Zhang, E. Mäkilä, J. Salonen, J. T. Hirvonen, H. A. Santos*, Adv. Mater. 2017, 29, 1603239.
[6] F. Fontana, M. Fusciello, C. Groeneveldt, C. Capasso, J. Chiaro, S. Feola, Z. Liu, E. M. Mäkilä, J. J. Salonen, J. T. Hirvonen, V. Cerullo*, H. A. Santos*, ACS Nano 2019, 13, 6477.
[7] T. Yong, X. Zhang, N. Bie, H. Zhang, X. Zhang, F. Li, A. Hakeem, J. Hu, L. Gan, H. A. Santos*, X. Yang*, Nature Commun. 2019, 10, 3838.
[8] M. Fusciello, F. Fontana, S. Tähtinen, C. Capasso, S. Feola, B. Martins, J. Chiaro, K. Peltonen, L. Ylösmäki, E. Ylösmäki, F. Hamdan, O. K. Kari, J. Ndika, H. Alenius, A. Urtti, J. T. Hirvonen, H. A. Santos*, V. Cerullo*, Nature Commun. 2019, 10, 5747.
[9] J. Zhang, Cheng Ji, Hongbo Zhang, Hui Shi, Fei Mao, Hui Qian, Wenrong Xu, Dongqing Wang, Jianming Pan, Xinjian Fang*, Hélder A. Santos*, Xu Zhang*, Sci. Adv. 2022, 8, eabj8207.
 

 

Short CV: Prof. Santos (D.Sc. Tech., Chem. Eng.) is a Full Professor in the Department of Biomedical Engineering and Head of the Department of Biomedical Engineering at the University of Groningen/University Medical Center Groningen. He was previously Full Professor in Pharmaceutical Nanotechnology, Director of Doctoral Program in Drug Research (University of Helsinki), Fellow Member of Helsinki Institute of Life Science, Director of the FinPharmaNet in Finland, and Chair of CRS Focus Group in Nanomedicine and Nanoscale Delivery. He is also Research Director and Head of Nanomedicines and Biomedical Engineering Group at the University of Helsinki, Faculty of Pharmacy. Prof. Santos is also the Chairman and co-founder of Capsamedix Oy, and Coordinator of H2020 EU MSCA-ITN P4 FIT network. He holds Visiting Professorships at the Shanghai Jiao Tong University School of Medicine (China) and University of Tartu (Estonia). 
Prof. Santos research interests include the development of nanoparticles/nanomedicines and biomaterials for biomedical applications, particularly cancer and heart diseases. His lab makes the unique bridge between medical engineering, pharmaceutical nanotechnology and tissue engineering by combining unique techniques to develop novel therapeutic formulations, including industrial scale-up validation, batch-to-batch reproducibility, and controllability of the biomaterials’ physicochemical properties for translation into the clinic. 
He is co-author of +400 publications (+14500 citations; h-index = 70) and 4 patents. He has +181 invited talks around the world. Prof. Santos has received prestigious awards/grants, e.g., the "Talent Prize in Science" in 2010 attributed by the Portuguese Government, ERC Starting Grant in 2013 and ERC Proof-of-Concept Grant in 2018, Young Researcher Award in 2013 attributed by Faculty of Pharmacy, the Academy of Finland Award for Social Impact in 2016, and the CRS Young Investigator Award 2021.

GuestSeminars@UCIBIO | Hélder A. Santos